Therefore, the development of SMYD2 inhibitors is expected to be a crucial step in the development of cancer therapeutics, and the development of other approaches to regulate SMYD2, such as miRNAs, that can be combined with these inhibitors is anticipated to result in synergistic effects in important cancer treatments. This evidence concerns the gene SMYD2 and cancer.